Medtronic (MDT) fundamentals: P/E, valuation, undervalued?
Medtronic · Health Care · ref. ETF XLV · price $93.01
In short — Medtronic trades at 22.9× earnings (P/E), 14.5× forward, with a net margin of 13.9 % and revenue growth of +14 %. Read: Cheap for the growth (P/E 15 for ~41% growth (PEG 0.4)).
Is Medtronic stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$93.01-3.7% over range
Oct 14, 25low $73.75 · high $105.35Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
69% recommend buying · 16 analysts
Valuation : Cheap for the growth — P/E 15 for ~41% growth (PEG 0.4)
Valuation
22.9
P/E (price/earnings)
14.5
Forward P/E
0.56
PEG
2.4
Price/book (P/B)
$119.0B
Market cap
4.07
EPS
Profitability & growth
13.9 %
Net margin
+14 %
Revenue growth
+41 %
Earnings growth
$28.2B
Total debt
Medtronic income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2023 | $31.2B | $3.8B | 12.0 % |
| 2024 | $32.4B | $3.7B | 11.4 % |
| 2025 | $33.5B | $4.7B | 13.9 % |
| 2026 | $36.3B | $4.8B | 13.2 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Medtronic's P/E and is the stock undervalued? What's a good P/E?
Medtronic's P/E is 22.9 (forward 14.5). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Medtronic profitable?
Medtronic has a net margin of 13.9 % (EPS 4.07). The company is profitable.
Is MDT stock expensive?
Our read: "Cheap for the growth" — P/E 15 for ~41% growth (PEG 0.4). Cross-check with growth and sector.
💬 A question about Medtronic? The JPI assistant answers using our backtest data.